FEB 22, 2016 02:42 PM PST

New T-Cell Leukemia Treatment Target Identified

WRITTEN BY: Kara Marker
Around 15 to 20 percent of children with acute lymphoblastic leukemia (ALL) have cancerous cells derived from T lymphocytes (immune cells), as opposed to B lymphocytes (American Cancer Society). Currently, over half of adults and 20 percent of children with T-cell ALL end up dying. New research from Boston University Medical College (BUMC) researchers offers a potential solution for lowering those fatality rates; their new study published in Leukemia  identifies a specific enzyme that cancer cells rely on for survival.
 

 
During the tricarboxylic acid (TCA) cycle, a key step in the process of cellular aerobic respiration, cells transform pyruvate received from glycolysis into energy through oxidation of acetyl-CoA (Georgia State University). The new BUMC study identified a key enzyme involved in this process called DLST, which cancer cells require for adequate growth and survival. They discovered the cancer cell dependence on DLST by performing genetic screenings on a zebrafish model of disease, looking for specific mutations that suppress tumor development.
 
Indeed, inhibiting DLST in the zebra fish model “significantly delayed tumor onset in zebrafish without detectable effects on fish development” (Leukemia 2016). They also successfully tested DLST enzyme activity inhibition with human T-cell leukemia cells.
 
A new prospect for T-cell ALL treatment utilizing DLST inhibition is promising, especially because current treatments for this cancer are highly toxic even if they are successful in healing the patient. This finding is also significant because prior to this research, scientists did not believe that cancer cells relied on the TCA cycle for survival.
 
“Our new findings provide solid evidence that these cancer cells depend on the TCA cycle for their survival," explained corresponding author Hui Feng, MD, PhD. "Additionally we demonstrated the importance of DLST in T-cell leukemia development, and have identified a targetable enzyme for T-cell leukemia treatment.”
 

Source: BUMC
 
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
AUG 02, 2018
Immunology
AUG 02, 2018
Chronic Infections Outsmart the Immune System
Chronic parasitic infection shown to take advantage of a mechanism to sustain infection and induce death of white blood cells essential to immune response....
OCT 03, 2018
Immunology
OCT 03, 2018
Let's Cut the Brakes on the Immune System
Two laureates receive Nobel Prize for their work regarding immune checkpoint therapy...
OCT 09, 2018
Drug Discovery
OCT 09, 2018
'Copper Antibiotic Peptide' Effective in Eradicating Tuberculosis
The bacterium responsible for Tuberculosis has found a way to avoid antibiotics by hiding inside the macrophages which are the specific immune cells that a...
NOV 07, 2018
Drug Discovery
NOV 07, 2018
Modifying Antibiotics For Drug Resistant Infections
In a study published in Nature Chemistry, researches at MIT were able to create a new chemical reaction that has the ability to modify antibiotics to make ...
NOV 13, 2018
Immunology
NOV 13, 2018
What Do Heart Disease and Autoimmune Diseases Have in Common?
Researchers at Washington University identify the link between autoimmune diseases and heart disease in mouse model...
NOV 19, 2018
Cell & Molecular Biology
NOV 19, 2018
How Mitochondria can Help the Cell Fight Pathogens
Some pathogens can get around out bodies' natural defense mechanisms. So our body developed a Plan B....
Loading Comments...